John Schieszer

1 week ago | renalandurologynews.com | John Schieszer

Light-activated TLD-1433 photodynamic therapy (PDT) may be a viable treatment option for select patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS; with or without papillary disease). An investigator presented “encouraging” interim results from a phase 2 clinical trial of the light-activated small molecule at the American Urological Association annual meeting in Las Vegas, Nevada.

2 weeks ago | northwestprimetime.com | John Schieszer

Older adults are expressing their discontent with medication barriers. A large majority of older Americans feel that health insurance, including Medicare, should cover anti-obesity medications, according to a new University of Michigan study. More than half of older adults who meet criteria for obesity said they were interested in trying one of these drugs to manage their weight.

2 weeks ago | renalandurologynews.com | John Schieszer

The CISTO study assessed patient-important outcomes after radical cystectomy (RC) and bladder-sparing therapy (BST), both standard of care treatment options for recurrent high-grade non-muscle invasive bladder cancer (NMIBC). Surprisingly, patient-prioritized outcomes were similar or better among patients choosing RC rather than BST, an investigator reported at a late-breaking session at the American Urological Association 2025 meeting in Las Vegas, Nevada.

2 weeks ago | renalandurologynews.com | John Schieszer

A randomized trial found a similar stone-free rate after pulse-modulated Holmium:YAG (Ho:YAG) laser vs thulium fiber laser (TFL) treatment of kidney stones. An investigator reported trial data during a late-breaking study session at the American Urological Association annual meeting in Las Vegas, Nevada. The trial findings suggest surgeon and institutional preferences may be the best approach when selecting which laser to use, according to Margaret A.

2 weeks ago | renalandurologynews.com | John Schieszer

The Hugo™ robotic-assisted surgery (RAS) system is safe and effective, according to late-breaking data presented at the American Urological Association 2025 meeting in Las Vegas, Nevada. The Hugo™ RAS system, currently used in more than 25 countries, is being investigated for use in the United States. The Expand URO study is a prospective, multi-center, single arm study of patients undergoing radical prostatectomy, partial or radical nephrectomy, or radical cystectomy.